Pancreatic Cancer Organoids Recapitulate Disease and Allow Personalized Drug Screening
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening Else Driehuisa,b, Arne van Hoecka,c, Kat Moored, Sigrid Koldersa,b, Hayley E. Franciese, M. Can Gulersonmezf, Edwin C. A. Stigterf, Boudewijn Burgeringf, Veerle Geurtsa,b, Ana Gracaning, Gergana Bounovad, Folkert H. Morsinkh, Robert Vriesg, Sylvia Bojg, Johan van Esa,b, G. Johan A. Offerhaush, Onno Kranenburgi, Mathew J. Garnette, Lodewyk Wesselsd, Edwin Cuppena,c,j,k, Lodewijk A. A. Brosensh, and Hans Cleversa,b,l,1 aOncode Institute, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands; bHubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, 3584 CT Utrecht, The Netherlands; cCenter for Molecular Medicine, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands; dDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; eWellcome Sanger Institute, Hinxton CB10 1SA, United Kingdom; fDepartment of Molecular Cancer Research, Center Molecular Medicine, Oncode Institute, University Medical Center Utrecht, Utrecht 3584 CM, The Netherlands; gHubrecht Organoid Technology, Utrecht 3584 CM, The Netherlands; hDepartment of Pathology, University Medical Center Utrecht, Utrecht 3584 CM, The Netherlands; iUtrecht Platform for Organoid Technology, Utrecht Medical Center Utrecht, Utrecht 3584 CM, The Netherlands; jHartwig Medical Foundation, 1098 XH Amsterdam, The Netherlands; kCenter for Personalized Cancer Treatment,University Medical Center Utrecht, Utrecht 3584 CM, The Netherlands; and lPrincess Maxima Center, Utrecht 3584 CS, The Netherlands Contributed by Hans Clevers, November 4, 2019 (sent for review July 5, 2019; reviewed by Anirban Maitra and Hugo Vankelecom) We report the derivation of 30 patient-derived organoid lines for personalized drug screening.
[Show full text]